FDA Approves 3-Month Leuprolide Mesylate 21 mg Formulation for Advanced Prostate Cancer
The FDA has approved a ready-to-use long-acting injectable formulation that is administered every 3 months as a treatment for advanced…
Many Patients With Statin Intolerance Self-Medicate, Despite No Link to Lowering LDL-C
Self-medication, including the use of dietary supplements and pain relief drugs, were reported by many patients with statin-associated muscle symptoms…
Rising 340B Costs Drive Employer Spending and Spark Calls for Reform
Employers are facing higher costs and employees higher premiums as 340B’s growth drives lost rebates and rising drug prices.
Abemaciclib Plus Endocrine Therapy Improves Survival in Patients With HR+/HER2– Breast Cancer
Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.
Expert: With New COVID-19 Vaccine Approvals, Pharmacists Should Remain Vigilant
Allison Hill, PharmD, RPh, emphasized that pharmacists must stay updated on ACIP and state-level guidance following HHS’s changes to COVID-19…
New Nanoparticle Treatment Shows Promise for Preventing Rheumatoid Arthritis Flares
An immunomodulatory nanoparticle called Agg-CLNP has been shown to effectively prevent disease onset for rheumatoid arthritis (RA).
Pneumococcal Positivity Associated With More Severe COVID-19 Outcomes
Patients with severe COVID-19 who tested positive for Streptococcus pneumoniae had higher mortality rates.
FDA Approves REMS Modification for Sparsentan in IgA Nephropathy
The FDA updated sparsentan’s REMS, easing monitoring requirements, enhancing treatment access for IgA nephropathy patients, and supporting kidney function preservation.
FDA Approves Generic Version of Liraglutide Injection, a GLP-1 for Weight Loss
Generic liraglutide injection is the first GLP-1 indicated for weight loss.